Table 3.

Qualitative MRI features in the wild-type p53 group and mutant p53 group

Feature	Wild-type p53 group	Mutant p53 group	p-value
Side of tumour epicentre			0.100
Unilateral	18/24 (75.0%)	31/33 (93.9%)
Center/Bilateral	6/24 (25.0%)	2/33 (6.1%)
Enhancement quality			0.189
Marked/Avid	16/24 (66.7%)	27/33 (81.8%)
Minimal/Mild	8/24 (33.3%)	6/33 (18.2%)
Cysts			0.954
Yes	10/24 (41.7%)	14/33 (42.4%)
No	14/24 (58.3%)	19/33 (57.6%)
Definition of the enhancing margin			0.813
Well-defined	8/24 (33.3%)	12/33 (36.4%)
Poorly defined	16/24 (66.7%)	21/33 (63.6%)
Definition of the non-enhancing margin			0.919
Smooth	4/24 (16.7%)	4/33 (12.1%)
Irregular	20/24 (83.3%)	29/33 (87.9%)
Oedema crosses midline			1.000
Yes	2/24 (8.3%)	3/33 (9.1%)
No	22/24 (91.7%)	30/33 (90.9%)
Haemorrhage			0.088
Yes	5/24 (20.8%)	14/33 (42.4%)
No	19/24 (79.2%)	19/33 (57.6%)
Pial invasion			0.085
Yes	9/24 (37.5%)	20/33 (60.6%)
No	15/24 (62.5%)	13/33 (39.4%)
Ependymal invasion			0.502
Yes	2/24 (8.3%)	6/33 (18.2%)
No	22/24 (91.7%)	27/33 (81.8%)
Cortical involvement			1.000
Yes	22/24 (91.7%)	30/33 (90.9%)
No	2/24 (8.3%)	3/33 (9.1%)
Deep WM invasion			0.337
Yes	14/24 (58.3%)	15/33 (45.5%)
No	10/24 (41.7%)	18/33 (54.5%)
nCET tumour crosses midline			0.616
Yes	3/24 (12.5%)	7/33 (21.2%)
No	21/24 (87.5%)	26/33 (78.8%)
Enhancing tumour crosses midline			0.009*
Yes	0/24 (0%)	10/33 (30.3%)
No	24/24 (100%)	23/33 (69.7%)
Satellites			0.346
Yes	4/24 (16.7%)	9/33 (27.3%)
No	20/24 (83.3%)	24/33 (72.7%)
Calvarial remodelling			1.000
Yes	3/24 (12.5%)	4/33 (12.1%)
No	21/24 (87.5%)	29/33 (87.9%)

*p <0.05nCET: non-contrast-enhancing tumour.